Compare GRPN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | CGEM |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.4M | 671.7M |
| IPO Year | 2011 | 2021 |
| Metric | GRPN | CGEM |
|---|---|---|
| Price | $16.20 | $9.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $31.25 | $28.00 |
| AVG Volume (30 Days) | 978.3K | ★ 1.5M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $496,093,000.00 | N/A |
| Revenue This Year | $4.17 | N/A |
| Revenue Next Year | $10.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.21 | $5.68 |
| 52 Week High | $43.08 | $13.33 |
| Indicator | GRPN | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 44.82 |
| Support Level | $15.50 | $10.01 |
| Resistance Level | $17.46 | $13.10 |
| Average True Range (ATR) | 0.84 | 1.00 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 22.49 | 3.73 |
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.